UK Markets open in 4 hrs 14 mins

Deinove SA (DNVVF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.50000.0000 (0.00%)
At close: 10:18AM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.5000
Open0.5000
BidN/A x N/A
AskN/A x N/A
Day's range0.5000 - 0.5000
52-week range0.4706 - 4.0200
Volume1,895
Avg. volume90
Market cap15.181M
Beta (5Y monthly)0.78
PE ratio (TTM)N/A
EPS (TTM)-0.2330
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Issuance of 3rd tranche of €500,000 of notes convertibles into new shares

    Issuance of 3rd tranche of €500,000 of notes convertibles into new shares DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating DNV3837 in patients with severe Clostridioides difficile infection DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces today the is

  • Globe Newswire

    DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections

    DEINOVE announces a favorable opinion from the DSMB for the continuation of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections The DSMB1 considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the clinical trial The design of the second part of the trial has been modified to integrate the investigators' feedback DEINOVE (Euronext Growth Paris, ALDEI), a French biotech company, pioneer in the exploration and exploitation of

  • Globe Newswire

    Issuance of 2nd tranche of €500,000 of notes convertibles into new shares

    Issuance of 2nd tranche of €500,000 of notes convertibles into new shares DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating DNV3837 in patients with severe Clostridioides difficile infection DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces today the is